Literature DB >> 8104793

On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole.

F Albertioni1, G Juliusson, J Liliemark.   

Abstract

The pharmacokinetics of oral CdA (0.24 mg/kg) was studied in 4 patients (1 with hairy cell leukaemia and 3 with B-cell chronic lymphocytic leukaemia) to determine any effect of food and fasting with and without omeprazole. Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting. The time to reach maximum concentration (tmax) was delayed about 0.8 h after food intake. Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C. V. 0.26 with and C. V. 0.27 without). In conclusion, there was a small, though not statistically significant reduction in the bioavailability of CdA after food intake. Omeprazole did not significantly improve the bioavailability of CdA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104793     DOI: 10.1007/bf02440863

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration.

Authors:  J Liliemark; F Albertioni; M Hassan; G Juliusson
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

2.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

Authors:  S Seto; C J Carrera; M Kubota; D B Wasson; D A Carson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  Determination of 2-chloro-2'-deoxyadenosine in human plasma.

Authors:  J Liliemark; B Pettersson; G Juliusson
Journal:  Biomed Chromatogr       Date:  1991-11       Impact factor: 1.902

4.  On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans.

Authors:  J Liliemark; G Juliusson
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

Review 5.  Metabolism and action of purine nucleoside analogs.

Authors:  W Plunkett; P P Saunders
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

6.  Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

Authors:  G Juliusson; A Elmhorn-Rosenborg; J Liliemark
Journal:  N Engl J Med       Date:  1992-10-08       Impact factor: 91.245

Review 7.  Cladribine (2-chlorodeoxyadenosine)

Authors:  E Beutler
Journal:  Lancet       Date:  1992-10-17       Impact factor: 79.321

8.  2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.

Authors:  V M Santana; J Mirro; C Kearns; M J Schell; W Crom; R L Blakley
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

9.  2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

Authors:  A C Kay; A Saven; C J Carrera; D A Carson; D Thurston; E Beutler; L D Piro
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

10.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

Authors:  L D Piro; C J Carrera; D A Carson; E Beutler
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

View more
  8 in total

Review 1.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  The clinical pharmacokinetics of cladribine.

Authors:  J Liliemark
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

3.  Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver.

Authors:  F Albertioni; M Hassan; J Silberring; J Liliemark
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

4.  Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia.

Authors:  F Albertioni; L Herngren; G Juliusson; J Liliemark
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 6.  Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Authors:  H J Guchelaar; D J Richel; M R Schaafsma
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

7.  Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.

Authors:  Julie A Murphy; Jacklyn A Harris; Andrew J Crannage
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

8.  Application of population pharmacokinetics to cladribine.

Authors:  Synnöve Lindemalm; Radojka M Savic; Mats O Karlsson; Gunnar Juliusson; Jan Liliemark; Freidoun Albertioni
Journal:  BMC Pharmacol       Date:  2005-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.